Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntertek Group Regulatory News (ITRK)

Share Price Information for Intertek Group (ITRK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,714.00
Bid: 4,742.00
Ask: 4,744.00
Change: -30.00 (-0.63%)
Spread: 2.00 (0.042%)
Open: 4,780.00
High: 4,790.00
Low: 4,714.00
Prev. Close: 4,744.00
ITRK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Intertek Acquires QTI Laboratory

7 Jun 2007 11:00

Intertek Group plc (Intertek), a leading international provider ofquality and safety services to a wide range of industries, hasacquired Quantitative Technologies Inc. (QTI). QTI will operate in theIntertek OCA Division (Caleb Brett) Pharmaceutical Services group. £ QTI is a leading contract analytical research and developmentlaboratory that has been serving the pharmaceutical, medical deviceand drug delivery industry in North America for over 15 years,specialising in the pre-market launch stages of the drug and productdevelopment life cycle. QTI is located in Whitehouse, New Jersey withapproximately 60 staff and counts major global pharmaceuticalcompanies among its clients. The laboratory is highly regarded fortechnical expertise, rigorous compliance programs, and outstandingcustomer service - it is a current Good Manufacturing Practice (cGMP)facility in good standing with the US Food and Drug Administration(FDA). £ The acquisition further advances Intertek's strategic growth inexpert support services to the global pharmaceutical, medical deviceand drug delivery industry through the provision of state of the artanalytical services. £ CEO of Intertek's OCA Division (Caleb Brett), Mark Loughead,comments: "QTI has an outstanding reputation in the industry and willfurther expand our ability to support the pharmaceutical and relatedsectors for outsourced R&D and testing expertise." £ John Conti-Ramsden, Ph.D., global director for IntertekPharmaceutical Services, said: "The acquisition of QTI furtherdevelops Intertek's USA offering and global platform in the area ofpharmaceutical services. Intertek already provides a wide range oftesting services to pharmaceutical clients from its laboratories inEurope and Good Laboratory Practice (GLP) bio-analytical services fromthe Alta laboratories in California." £ Paul Winslow, Ph.D., managing director of QTI comments: "JoiningIntertek provides QTI a global network to access and serve theworldwide pharmaceutical industry. Additionally, Intertek's commitmentto growth will allow QTI to expand our capabilities to provide a morecomprehensive service offering to our key industry markets." £ About Intertek: £ Intertek Group plc (LSE:ITRK) is a leading international providerof quality and safety services to a wide range of global and localindustries. Partnership with Intertek brings increased value tocustomers' products and processes, ultimately supporting their successin the global market place. Intertek has the experience, expertise,resources and global reach to support its customers through theirnetwork of 930 laboratories and offices, 18,000 people in 109countries around the world. www.intertek.com £ About Intertek Pharmaceutical Services: £ Intertek's Pharmaceutical and Speciality Chemical Laboratoriesprovide a wide range of routine and non-routine laboratory testingservices to support pharmaceutical, biotechnology and nanotechnologyclients. A growing international network of Intertek laboratories andoffices serve clients from a wide range of industries on a globalbasis with services including laboratory testing, outsourcing,inspection, R&D and process services. Intertek laboratories areideally suited to support a diverse range of fine chemical,pharmaceutical and biotech activities. £ www.intertek-cb.com/pharma £ About QTI: £ QTI is a FDA and DEA registered contract Analytical Research &Development Laboratory, operating in accordance with cGMP regulationsand associated guidance documents. Located in Whitehouse, NJ, QTI hasbeen providing complete analytical solutions to the pharmaceutical andbiotechnology communities since 1989. QTI's mission is to exceedclients' expectations by providing innovative solutions for theiranalytical challenges and to help them achieve their technicalbusiness objectives while maintaining the highest level of qualityassurance and regulatory compliance. Copyright Business Wire 2007
Date   Source Headline
6th Jun 20241:00 pmRNSDirector/PDMR Shareholding
29th May 20241:00 pmRNSDirector/PDMR Shareholding
28th May 20247:00 amRNSDirectorate Change
24th May 20241:30 pmRNSResult of AGM
24th May 20247:00 amRNSTrading Statement
22nd May 20241:00 pmRNSBlock listing Interim Review
22nd Mar 20249:00 amRNSAnnual Financial Report
14th Mar 20241:00 pmRNSDirector/PDMR Shareholding
14th Mar 20241:00 pmRNSDirector/PDMR Shareholding
13th Mar 20241:00 pmRNSDirector/PDMR Shareholding
5th Mar 20247:00 amRNSFinal Results
4th Mar 20247:00 amRNSAcquisition
1st Mar 20241:00 pmRNSDirectorate Change
28th Feb 20241:00 pmRNSDirector/PDMR Shareholding
23rd Nov 20237:00 amRNSTrading Statement
22nd Nov 20231:00 pmRNSBlock listing Interim Review
14th Sep 20231:00 pmRNSDirector Declaration
24th Aug 20237:00 amRNSAcquisition
28th Jul 20237:00 amRNSHalf-year Report
12th Jul 202310:00 amRNSDirectorate Change
7th Jun 20231:00 pmRNSDirector/PDMR Shareholding
31st May 20231:00 pmRNSDirector/PDMR Shareholding
30th May 20233:00 pmRNSHolding(s) in Company
30th May 20231:00 pmRNSBlock listing Interim Review
24th May 202311:00 amRNSResult of AGM
24th May 20237:00 amRNSTrading Statement
3rd May 20237:00 amRNSCapital Markets Event
27th Apr 20234:00 pmRNSDirector Declaration
26th Apr 20234:30 pmRNSDirector Declaration
20th Apr 20234:00 pmRNSDirector Declaration
3rd Apr 20237:00 amRNSAcquisition
24th Mar 20239:00 amRNSNotice of 2023 AGM
21st Mar 20239:00 amRNSAnnual Financial Report
20th Mar 20237:00 amRNSDirectorate Change
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNSFinal Results
23rd Dec 202210:00 amRNSDirectorate Change
13th Dec 202211:00 amRNSDirector Declaration
12th Dec 20221:00 pmRNSDirector Declaration
24th Nov 20227:00 amRNSTrading Statement
21st Nov 20221:00 pmRNSBlock listing Interim Review
2nd Aug 20229:00 amRNSDirector/PDMR Shareholding
29th Jul 20227:01 amRNSAcquisition
29th Jul 20227:00 amRNSHalf-year Report
21st Jun 20221:00 pmRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSDirectorate Change
25th May 202211:00 amRNSResult of AGM
25th May 20227:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.